Experimental diabetes drug trial halted early – what happened?
NCT ID NCT06611930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called CK-0045 in 90 adults with type 2 diabetes and overweight or obesity. Participants received weekly injections of CK-0045 or a placebo for 16 weeks to see if it improved blood sugar after meals and reduced body weight. The trial was terminated early, so its effectiveness remains unknown.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CK-0045 (a lab-made protein that mimics interleukin-22)
What this could lead to
If it had worked, CK-0045 could have offered a new weekly injection to help control blood sugar and reduce weight in people with type 2 diabetes and obesity.
What could go wrong
The trial was terminated early, so results are not available. It was a small, early-phase study, and many such drugs fail to show benefit or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Reserach Services Mannheim GmbH
Mannheim, Baden-Wurttemberg, 68167, Germany
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, D-41460, Germany